Drug: Trimethoprim-Sulfamethoxazole 160
Phase 2Small molecule
Drug: Trimethoprim-Sulfamethoxazole 160 is one of 48 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
92 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Calciparine
BBaxter Healthcare Corporation
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Oraverse
LLife Extension Foundation Inc.
Phase 3
Northera
LundbeckPhase 2
Desferal
Jazz PharmaceuticalsPhase 2
Lamisil
NovartisPhase 2
Pitressin
AAultman Health Foundation
Phase 2
Arginine Vasopressin
SStanford University
Phase 3
Jardiance
Boehringer IngelheimPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHospital Civil de Guadalajara